Eden Biodesign develops and produces of a range of vaccine and gene therapy products derived from diverse virus types. Its cGMP manufacturing facility offers fully segregated viral production at a range of scales, using a various production technologies and processes, including a platform approach for the production of adenoviruses in stirred tank suspension culture.
Crawford Brown, Ph.D., chief executive officer of Eden Biodesign, said, “We are delighted to strengthen our relationship with Crucell and to be able to offer our services to Crucell’s PER.C6 licensees. We have demonstrated that the combination of Crucell’s proven and valuable technology and Eden Biodesign’s expertise in vaccine and gene therapy development and manufacturing delivers tremendous value to our customers by accelerating progression of products into and through clinical development, while maintaining the ability to scale-up production and achieve a highly attractive cost-of-goods.”